Exicure (XCUR) Competitors $13.23 +0.93 (+7.56%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$13.64 +0.41 (+3.10%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. DNA, TECX, ALLO, AMLX, BNTC, CYRX, ATXS, AURA, ALMS, and ARCTShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Ginkgo Bioworks (DNA), Tectonic Therapeutic (TECX), Allogene Therapeutics (ALLO), Amylyx Pharmaceuticals (AMLX), Benitec Biopharma (BNTC), Cryoport (CYRX), Astria Therapeutics (ATXS), Aura Biosciences (AURA), Alumis (ALMS), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Ginkgo Bioworks Tectonic Therapeutic Allogene Therapeutics Amylyx Pharmaceuticals Benitec Biopharma Cryoport Astria Therapeutics Aura Biosciences Alumis Arcturus Therapeutics Exicure (NASDAQ:XCUR) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership. Is XCUR or DNA more profitable? Exicure has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Ginkgo Bioworks' return on equity of -58.54% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -190.90% -36.75% Ginkgo Bioworks -298.78%-58.54%-34.24% Does the MarketBeat Community prefer XCUR or DNA? Ginkgo Bioworks received 15 more outperform votes than Exicure when rated by MarketBeat users. However, 47.37% of users gave Exicure an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformExicureOutperform Votes947.37% Underperform Votes1052.63% Ginkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Does the media favor XCUR or DNA? In the previous week, Ginkgo Bioworks had 3 more articles in the media than Exicure. MarketBeat recorded 4 mentions for Ginkgo Bioworks and 1 mentions for Exicure. Exicure's average media sentiment score of 0.69 beat Ginkgo Bioworks' score of 0.47 indicating that Exicure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of XCUR or DNA? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 3.9% of Exicure shares are owned by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better valuation & earnings, XCUR or DNA? Exicure has higher earnings, but lower revenue than Ginkgo Bioworks. Exicure is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K167.17-$16.91M-$4.81-2.75Ginkgo Bioworks$227.04M1.46-$892.87M-$10.68-0.53 Do analysts recommend XCUR or DNA? Ginkgo Bioworks has a consensus target price of $4.58, suggesting a potential downside of 19.81%. Given Ginkgo Bioworks' stronger consensus rating and higher possible upside, analysts clearly believe Ginkgo Bioworks is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ginkgo Bioworks 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60 Which has more risk & volatility, XCUR or DNA? Exicure has a beta of 3.84, meaning that its share price is 284% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. SummaryGinkgo Bioworks beats Exicure on 11 of the 18 factors compared between the two stocks. Remove Ads Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.59M$6.73B$5.54B$7.49BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-6.396.9923.2518.07Price / Sales167.17198.60361.2686.83Price / CashN/A65.6738.1634.64Price / Book7.565.926.493.99Net Income-$16.91M$142.37M$3.21B$247.18M7 Day Performance-5.50%-9.32%-6.42%-6.42%1 Month Performance16.87%-10.26%-0.68%-7.44%1 Year Performance2,262.50%-15.08%6.05%-4.31% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.0768 of 5 stars$13.23+7.6%N/A+2,262.5%$83.59M$500,000.00-6.3950DNAGinkgo Bioworks0.5678 of 5 stars$5.71-6.8%$4.58-19.8%N/A$331.08M$227.04M-0.44640Gap DownTECXTectonic Therapeutic2.9946 of 5 stars$17.71-5.0%$77.75+339.0%N/A$330.52MN/A-3.01120Gap DownHigh Trading VolumeALLOAllogene Therapeutics2.3359 of 5 stars$1.46-5.8%$9.29+536.2%-66.3%$317.21M$22,000.00-0.94310Gap DownAMLXAmylyx Pharmaceuticals2.6852 of 5 stars$3.54-3.3%$7.33+107.2%+33.5%$313.65M$87.37M-0.93200News CoverageGap DownBNTCBenitec Biopharma2.397 of 5 stars$13.01-3.1%$24.43+87.8%+134.8%$305.10M$80,000.00-8.6220Short Interest ↑Analyst RevisionCYRXCryoport2.5868 of 5 stars$6.08-0.2%$11.67+91.9%-70.3%$303.45M$228.39M-1.801,020Analyst ForecastGap DownHigh Trading VolumeATXSAstria Therapeutics1.471 of 5 stars$5.34-6.3%$26.60+398.1%-57.4%$301.36MN/A-2.5630Gap DownAURAAura Biosciences2.0989 of 5 stars$5.86-7.6%$23.00+292.5%-21.8%$294.32MN/A-3.3950Gap DownALMSAlumis2.7193 of 5 stars$6.14+8.9%$26.00+323.5%N/A$289.94MN/A0.00N/AInsider TradePositive NewsGap DownHigh Trading VolumeARCTArcturus Therapeutics3.1668 of 5 stars$10.59-8.5%$59.20+459.0%-71.0%$287.20M$138.39M-4.77180Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Ginkgo Bioworks Alternatives Tectonic Therapeutic Alternatives Allogene Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives Benitec Biopharma Alternatives Cryoport Alternatives Astria Therapeutics Alternatives Aura Biosciences Alternatives Alumis Alternatives Arcturus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XCUR Stock Free XCUR Stock Alerts